Basilea Pharmaceutica Ltd (BSLN.XSWX) Dividend Analysis
This company has no dividend history.
Based on TTM and annual data · Not a buy/sell signal
This company does not pay dividends
No dividend history found in company filings.
Does Basilea Pharmaceutica (BSLN.XSWX) pay a dividend?
Basilea Pharmaceutica (BSLN.XSWX) has never paid a dividend. The business does generate free cash flow of CHF 59 million, so the absence of a dividend is a capital-allocation choice rather than an inability to pay. All figures are computed from company filings; this is analysis, not investment advice.
Frequently asked
Does Basilea Pharmaceutica (BSLN.XSWX) pay a dividend?+
No. Basilea Pharmaceutica (BSLN.XSWX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold.
How does Basilea Pharmaceutica return cash to shareholders?+
It largely does not. Basilea Pharmaceutica pays no dividend and we do not see a meaningful reduction in share count over the last twelve months, so cash is being retained in the business or spent on growth rather than returned. That is common for companies reinvesting heavily, and it means your return depends entirely on the share price.
Could Basilea Pharmaceutica afford to pay a dividend?+
On the numbers, yes. Basilea Pharmaceutica generated CHF 59 million of free cash flow, which is about CHF 4.90 per share. If it paid out half of that, the dividend would be roughly CHF 2.45 per share, a yield of about 3.7% at the current price. That is an illustration of capacity, not a prediction: the company has given no indication it intends to pay one.
Which healthcare companies do pay dividends?+
Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with Basilea Pharmaceutica.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.